Tarun Chakravarty

Showing 1-11 of 11 articles

Author Tarun Chakravarty

Interventions for heart failure

Allogeneic Cardiosphere-derived Cells for the Treatment of Heart Failure with Reduced Ejection Fraction: Results of the Dilated cardiomYopathy iNtervention with Allogeneic Myocardially-regeneratIve Cells (DYNAMIC) trial

Chakravarty T, Henry TD, Kittleson M, Lima J, Siegel R, Slipczuk L, Pagoda JM, Smith RR, Malliaras K, Marbán L, Ascheim DD, Marbán E, Makkar R

November 26, 2019 | 10.4244/EIJ-D-19-00035

Author Tarun Chakravarty

Interventions for valvular disease

High-pressure post-dilation following transcatheter valve-in-valve implantation in small surgical valves

Chakravarty T, Cox J, Abramowitz Y, Israr S, Uberoi A, Yoon S, Dey D, Zadeh P, Cheng W, Makkar R

June 20, 2018 | 10.4244/EIJ-D-17-00563

Author Yigal Abramowitz

Characteristics and outcome following transcatheter aortic valve replacement in patients with severe aortic stenosis with low flow

Abramowitz Y, Chakravarty T, Pibarot P, Maeno Y, Kawamori H, Anderson D, Mangat G, Nakamura M, Cheng W, Makkar R

December 8, 2017 | 10.4244/EIJ-D-17-00139

Author Yoshio Maeno

Interventions for valvular disease

Optimal sizing for SAPIEN 3 transcatheter aortic valve replacement in patients with or without left ventricular outflow tract calcification

Maeno Y, Abramowitz Y, Jilaihawi H, Israr S, Yoon S, Sharma R, Kazuno Y, Kawamori H, Miyasaka M, Rami T, Mangat G, Takahashi N, Okuyama K, Kashif M, Chakravarty T, Nakamura M, Cheng W, Makkar R

April 7, 2017 | 10.4244/EIJ-D-16-00806

Author Tarun Chakravarty

Interventions for valvular disease

Leaflet motion abnormality after TAVI: genuine threat or much ado about nothing?

Chakravarty T, Abramowitz Y, Jilaihawi H, Makkar R

September 18, 2016 | 10.4244/EIJV12SYA7

Author Stylianos A. Pyxaras

Coronary interventions

Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment

Pyxaras S, Hunziker L, Chieffo A, Meliga E, Latib A, Park S-J, Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar R, Palacios I, Kim Y, Buszman P, Chakravarty T, Sheiban I, Mehran R, Margey R, Agnihotri A, Marra S, Capodanno D, Leon M, Moses J, Fajadet J, Lefèvre T, Morice M, Erglis A, Tamburino C, Alfieri O, Serruys P, Colombo A, Naber C

August 5, 2016 | 10.4244/EIJV12I5A102

Author Kazuaki Okuyama

Interventions for valvular disease

The clinical impact of vascular complications as defined by VARC-1 vs. VARC-2 in patients following transcatheter aortic valve implantation

Okuyama K, Jilaihawi H, Abramowitz Y, Kashif M, Patel J, Pokhrel H, Chakravarty T, Nakamura M, Cheng W, Makkar R

August 5, 2016 | 10.4244/EIJV12I5A104

Author Yigal Abramowitz

Interventions for valvular disease

Feasibility and safety of balloon-expandable transcatheter aortic valve implantation with moderate or without predilatation

Abramowitz Y, Jilaihawi H, Chakravarty T, Kashif M, Matar G, Hariri B, Patel J, Sharma R, Cheng W, Makkar R

February 19, 2016 | 10.4244/EIJV11I10A229

Author Yigal Abramowitz

Clinical impact of coronary protection during transcatheter aortic valve implantation: first reported series of patients

Abramowitz Y, Chakravarty T, Jilaihawi H, Kashif M, Kazuno Y, Takahashi N, Maeno Y, Nakamura M, Cheng W, Makkar R

September 22, 2015 | 10.4244/EIJV11I5A112

Author Hasan Jilaihawi

Heart-rate adjustment of transcatheter haemodynamics improves the prognostic evaluation of paravalvular regurgitation after transcatheter aortic valve implantation

Jilaihawi H, Chakravarty T, Shiota T, Rafique A, Harada K, Shibayama K, Doctor N, Kashif M, Nakamura M, Mirocha J, Rami T, Okuyama K, Cheng W, Sadruddin O, Siegel R, Makkar R

August 20, 2015 | 10.4244/EIJY14M12_08

Author Emanuele Meliga

Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry

Meliga E, De Benedictis M, Chieffo A, Latib A, Park S-J, Kim Y, Onuma Y, Capranzano P, Jegere S, Makkar R, Palacios I, Buszman P, Bande M, Chakravarty T, Mehran R, Naber C, Scrocca I, Margey R, Leon M, Moses J, Fajadet J, Lefèvre T, Morice M, Erglis A, Tamburino C, Alfieri O, Conte M, Serruys P, Colombo A

November 29, 2013 | 10.4244/EIJV9I7A133

1

Latest news

Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue

(Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right))

December 6, 2019

Discover 5 new trials: GALILEO, CONDI-2/ERIC-PCI, EVOLUTE II-5 years, SCOPE and Excel 5 years

(The Trials book is supported by Biotronik)

December 13, 2019

New this week: A Dose-response Meta Analysis, stroke after MitraClip and more

December 10, 2019

The challenge of innovation for the (interventional?) cardiology world

December 6, 2019

Guidance Papers

Guidelines, consensus & position papers

2019 – A leap year for valvular heart disease

(Course directors PCR London Valves 2019)

November 15, 2019

Last week's JAA's: EXTREME Study, Stent Optimization and more

December 3, 2019

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke